Tucson, AZ (PRWEB) January 26, 2015 -- Convoy Therapeutics, Inc. announced today that M.I.T. Institute Professor Robert Langer, Sc.D. has joined the company’s Scientific Advisory Board. Dr. Langer, is one the foremost engineers in the world today. Dr. Langer has nearly 1,100 patents worldwide. He has been honored with more than 220 awards including the Lemelson-M.I.T. Innovation Prize, Kyoto Prize, National Medal of Innovation and Technology, and the United States National Medal of Science and has served as chairman of the FDA's highest advisory board. Both Forbes and Bio World have named Dr. Langer one of the 25 most important individuals in biotechnology in the world.
Commenting on the appointment, Convoy's Chief Executive Officer, John Muraski, Ph.D., said, "Dr. Langer brings unique expertise and depth to Convoy Therapeutics. His tremendous experience with delivery technology allows us to continue to improve our platform and pipeline.”
Dr. Langer stated, "I'm very excited to be working with Convoy. Their SPACE platform has the potential to be a truly disruptive technology."
Convoy Therapeutics is an innovative therapeutics company applying its proprietary SPACE (Skin Penetrating and Cell Entering) platform technology to improve topical treatment options for patients with dermatological disease. The unique peptide based platform enables large and small molecules to penetrate into the skin and remain localized for improved therapeutic effectiveness with limited systemic absorption. The company has preclinical programs in psoriasis, eczema, and acne, and one platform-developed asset set to be commercialized through partners and a second asset poised for internal clinical development.
Dr. Langer bolsters Convoy’s already strong team of advisors. Mara Aspinall, Former President and CEO of Ventana Medical Systems, and Aron Stern, Chief Administrative Officer of Vital Therapies, are both Strategic Advisors.
Debbie Rinaldi, Director Investor Relations, Convoy Therapeutics, http://www.convoytx.com, +1 503.550.8798, [email protected]
SOURCE Convoy Therapeutics